Targeting EGFR Exon 20 Insertions in NSCLC: Current and Future Prospects

62-21-648-WC WCLC Concept_001

Activity Overview

This activity begins by providing guidance on identifying EGFR exon 20 insertion mutations in advanced non-small cell lung cancer (NSCLC) and information on their therapeutic relevance. New and emerging therapeutic options are discussed, with an emphasis on the most recently presented and/or published clinical data. Learners will also receive privileged insights into the optimal management of potential adverse effects.

0.75 CE Credit(s)
Expires: October 26, 2022

Target Audience

This activity is intended for medical oncologists, pathologists, pulmonologists, and other clinicians who are involved in the management of patients with advanced non-small cell lung cancer (NSCLC).

Learning Objectives

Upon successful completion of this education activity, participants should be better able to:

  • Analyze the predictive/prognostic significance of EGFR exon 20 insertion mutations in non-small cell lung cancer (NSCLC)
  • Apply optimal diagnostic strategies for identifying NSCLC with EGFR exon 20 insertions
  • Assess clinical trial data regarding new and emerging treatment options for advanced NSCLC with EGFR exon 20 insertions
  • Employ appropriate techniques to manage adverse events associated with EGFR inhibition

Activity Faculty

Mok_300x400

Professor Tony S.K. Mok, BMSc, MD, FRCP(C), FRCP(Edin), FHKCP, FHKAM(Medicine), FASCO

Li Shu Fan Medical Foundation Professor, Clinical Oncology
The Chinese University of Hong Kong
Hong Kong, China

Shirish_300x400

Shirish M. Gadgeel, MD

Chief, Division of Hematology and Oncology
Department of Internal Medicine
Henry Ford Cancer Institute/Henry Ford Health System
Detroit, MI

Passaro_300x400

Antonio Passaro, MD, PhD

Medical Oncologist, Division of Thoracic Oncology
European Institute of Oncology
Milan, Italy